Bajaj Healthcare has received approval from India's Drug Controller General to manufacture Pimavanserin, a drug for Parkinson's-related hallucinations and delusions. Pimavanserin, already popular in ...
Bajaj Finance reported a 17% growth in consolidated net profit for the third quarter of FY25 at ₹4,247 crore as against ₹3,639 crore in the year ago period.
Its consolidated total income rose by 10 per cent to Rs 32,042 crore in the reporting quarter (Q3FY25), from Rs 29,038 crore in the year-ago period ...